Antipsychotic drugs differ in their propensity to cause extrapyramidal side-effects (EPS), but
their dose-effects are unclear. Therefore, we conducted a systematic review and dose …

Abstract Model-informed drug development (MIDD) is a powerful approach to support drug
development and regulatory review. There is a rich history of MIDD applications at the US …

Despite considerable progress in pharmacotherapy over the past seven decades, many
mental disorders remain insufficiently treated. This situation is in part due to the limited …

The negative symptoms of schizophrenia, which often appear earlier than any other
symptom, are prominent and clinically relevant in the majority of patients. As a result, interest …

Randomized controlled trials (RCTs) have been considered as gold standard for
establishing the efficacy and safety of investigational new drugs; nonetheless, the …

Background: There is an urgent need to develop more effective and safer antipsychotics
beyond dopamine 2 receptor antagonists. An emerging and promising approach is TAAR1 …

In the past decade, biopharmaceutical research and development in China has been
notably boosted by government policies, regulatory initiatives and increasing investments in …

Background Non-invasive brain stimulation (NIBS) is a promising intervention for treatment-
resistant schizophrenia. However, there are multiple available techniques and a …

This paper empirically examines whether integrating entrepreneurial abilities with the theory
of perceived behaviour positively influences Sustainable-Development-Goal-8-driven …

Background Differences in trial design may affect estimates of efficacy of psychotropic drugs.
The purpose of this meta-analysis is to evaluate whether the use of Olanzapine (OLZ) as …